Neos Therapeutics Statement: COVID-19 Update
We want to share the steps we are taking to ensure healthcare providers and patients continue to receive support from
To help slow the spread of COVID-19, most of our employees have been operating under a work from home policy in accordance with guidance issued by the
Neos currently markets Adzenys XR-ODT®, Cotempla XR-ODT®, Adzenys-ER® for the treatment of ADHD and Generic Tussionex. All of our products are available to patients, and we have approximately 4 months of inventory on hand to meet market demand. Neos continues to closely monitor supply levels and will work diligently to mitigate disruption to patients, should any arise. Our Neos RxConnect patient support program remains operational and available to all commercially ensured patients. If providers or patients have questions, please call 1-877-875-6590.
We continue to expect that the Phase 1 ascending dose study of NT0502 will be initiated in the second half of 2020. We will provide an update if this timeline is impacted by COVID-19.
We are committed to continuing to implement measures intended to minimize any potential business impact from COVID-19, including implementing cost cutting measures, and we will continue to closely monitor, assess and respond to the situation as it evolves.
Chief Financial Officer
Stern Investor Relations, Inc.
Source: Neos Therapeutics, Inc.